A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.

The development of clinically viable delivery methods presents one of the greatest challenges in the therapeutic application of CRISPR/Cas9 mediated genome editing. Here, we report the development of a lipid nanoparticle (LNP)-mediated delivery system that, with a single administration, enabled significant editing of the mouse transthyretin (Ttr) gene in the liver, with a >97% reduction in serum protein levels that persisted for at least 12 months. These results were achieved with an LNP delivery system that was biodegradable and well tolerated. The LNP delivery system was combined with a sgRNA having a chemical modification pattern that was important for high levels of in vivo activity. The formulation was similarly effective in a rat model. Our work demonstrates that this LNP system can deliver CRISPR/Cas9 components to achieve clinically relevant levels of in vivo genome editing with a concomitant reduction of TTR serum protein, highlighting the potential of this system as an effective genome editing platform.

[1]  D. Peter Tieleman,et al.  Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core , 2012, The journal of physical chemistry. C, Nanomaterials and interfaces.

[2]  Daniel G. Anderson,et al.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.

[3]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[4]  Kenneth J. Longmuir,et al.  Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis , 2009, Histochemistry and Cell Biology.

[5]  John C. Rose,et al.  Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics , 2017, Nature Methods.

[6]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[7]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[8]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[9]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[10]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[12]  L. J. Lee,et al.  Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[13]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[14]  P. Cullis,et al.  Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo , 2016, Molecular therapy. Nucleic acids.

[15]  Akin Akinc,et al.  Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles , 2013, Molecular therapy. Nucleic acids.

[16]  E. Pikarsky,et al.  Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. , 2014, Cell stem cell.

[17]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[18]  R. Nusse,et al.  Self-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver , 2015, Nature.

[19]  S. Bertholet,et al.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge , 2016, PloS one.

[20]  Hans Clevers,et al.  In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration , 2013, Nature.

[21]  I. Maclachlan,et al.  Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA , 2014, Science Translational Medicine.

[22]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[23]  B. Steensel,et al.  Quantitative analysis shows that repair of Cas9-induced double-strand DNA breaks is slow and error-prone , 2017, bioRxiv.

[24]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[25]  Justin M. Richner,et al.  Modified mRNA Vaccines Protect against Zika Virus Infection , 2017, Cell.

[26]  Bin Zhou,et al.  Genetic tracing of hepatocytes in liver homeostasis, injury, and regeneration , 2017, The Journal of Biological Chemistry.

[27]  M. Kay,et al.  Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. , 2011, The Journal of clinical investigation.

[28]  Xiurui Zhu,et al.  A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo , 2017, Cell Research.

[29]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[30]  Florian Schmidt,et al.  CRISPR genome engineering and viral gene delivery: A case of mutual attraction , 2015, Biotechnology journal.